Saturation Binding of Nicotine to Synthetic Neuromelanin Demonstrated by Fluorescence Spectroscopy

[1]  The desferrioxamine-prochlorperazine coma—clue to the role of dopamine-iron recycling in the synthesis of hydrogen peroxide in the brain , 2014, Front. Mol. Neurosci..

[2]  Laura M. Vecchio,et al.  Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo , 2014, Proceedings of the National Academy of Sciences.

[3]  N. Lindquist,et al.  Melanin affinity and its possible role in neurodegeneration , 2013, Journal of Neural Transmission.

[4]  T. Gasser,et al.  The Application of Clinical Genetics Dovepress Genetic Basis of Parkinson's Disease: Inheritance, Penetrance, and Expression , 2022 .

[5]  A. A. Farooqui,et al.  Lipid-Mediated Oxidative Stress and Inflammation in the Pathogenesis of Parkinson's Disease , 2011, Parkinson's disease.

[6]  M. Quik,et al.  Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys , 2009, Journal of neurochemistry.

[7]  D. Sulzer,et al.  Intraneuronal dopamine-quinone synthesis: A review , 1999, Neurotoxicity Research.

[8]  J. Geiger,et al.  Caffeine protects against MPTP‐induced blood‐brain barrier dysfunction in mouse striatum , 2008, Journal of neurochemistry.

[9]  A. Lauria,et al.  Intercalation of Daunomycin into Stacked DNA Base Pairs. DFT Study of an Anticancer Drug , 2008, Journal of biomolecular structure & dynamics.

[10]  C. Davie.  A review of Parkinson's disease. , 2008, British medical bulletin.

[11]  A. Lees.  Unresolved issues relating to the Shaking Palsy on the celebration of James Parkinson's 250th birthday , 2007, Movement disorders : official journal of the Movement Disorder Society.

[12]  R. Fariello,et al.  A proposed dual role of neuromelanin in the pathogenesis of Parkinson’s disease , 2006, Neurology.

[13]  G. Edwards,et al.  The surface oxidation potential of human neuromelanin reveals a spherical architecture with a pheomelanin core and a eumelanin surface , 2006, Proceedings of the National Academy of Sciences.

[14]  Louise K. Charkoudian,et al.  Fe(III)-coordination properties of neuromelanin components: 5,6-dihydroxyindole and 5,6-dihydroxyindole-2-carboxylic acid. , 2006, Inorganic chemistry.

[15]  J. Choi,et al.  Immobilization stress causes increases in tetrahydrobiopterin, dopamine, and neuromelanin and oxidative damage in the nigrostriatal system , 2005, Journal of neurochemistry.

[16]  P. Riederer,et al.  Dolichol is the major lipid component of human substantia nigra neuromelanin , 2005, Journal of neurochemistry.

[17]  Alberto Gatti,et al.  The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Bin Liu,et al.  Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  John D Simon,et al.  Isolation and biophysical studies of natural eumelanins: applications of imaging technologies and ultrafast spectroscopy. , 2003, Pigment cell research.

[20]  K. Wakamatsu,et al.  The structure of neuromelanin as studied by chemical degradative methods , 2003, Journal of neurochemistry.

[21]  P. Riederer,et al.  Influence of neuromelanin on oxidative pathways within the human substantia nigra. , 2002, Neurotoxicology and teratology.

[22]  D. Sulzer,et al.  Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour , 2001, Molecular pathology : MP.

[23]  L. Greene,et al.  Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S. Ito,et al.  Interaction of Human Substantia Nigra Neuromelanin with Lipids and Peptides , 2000, Journal of neurochemistry.

[25]  R. Ramsay,et al.  Biochemical Events in the Development of Parkinsonism Induced by 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine , 1987, Journal of neurochemistry.

[26]  S. Snyder,et al.  Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. , 1986, Science.

[27]  S. Snyder,et al.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.